| Identification | Back Directory | [Name]
4-(5-{[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)pyridine | [CAS]
919936-70-2 | [Synonyms]
GS87
4-[5-[[(3-Phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]pyridine
Pyridine, 4-[5-[[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]-
4-(5-{[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)pyridine
GS-87,GSK3α,GSK-3,Inhibitor,Glycogen synthase kinase 3,MAPK,GS 87,inhibit,Glycogen synthase kinase-3,GSK3,GS87,AML,differentiation,GSK3β | [Molecular Formula]
C16H11N5O2S | [MOL File]
919936-70-2.mol | [Molecular Weight]
337.36 |
| Hazard Information | Back Directory | [Uses]
GS87 is a highly specific and potent GSK3 inhibitor with IC50s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research[1]. | [IC 50]
GSK3α: 415 nM (IC50); GSK3β: 521 nM (IC50) | [References]
[1] Sophia Hu, et al. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Mol Cancer Ther. 2016 Jul;15(7):1485-1494. DOI:10.1158/1535-7163.MCT-15-0566 |
|
|